<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04371172</url>
  </required_header>
  <id_info>
    <org_study_id>32-249 ex 19/20</org_study_id>
    <secondary_id>32-249 ex19/20</secondary_id>
    <nct_id>NCT04371172</nct_id>
  </id_info>
  <brief_title>Impact of TAVI on Cognition, Mood and Health-related Quality of Life</brief_title>
  <official_title>The Impact of Transcatheter Aortic Valve Implantation on Cognition, Mood and Health-related Quality of Life - an Explorative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed study, patients with and without embolic protection devices during
      Transcatheter Aortic Valve Implantation will be repeatedly examined with a comprehensive
      psychiatric and cognitive test battery over a post-interventional period of 6 months after
      TAVI, with regard to the effects on mood, cognitive Performance and health-related Quality of
      life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The percutaneous aortic valve replacement (TAVI, Transcatheter Aortic Valve Implantation)
      enables the implantation of a new biological aortic valve at the beating heart. The procedure
      is performed under local anaesthesia and is a gold standard in the therapy of aortic
      stenosis, especially in patients with a too high health risk for cardiovascular surgery.

      In the proposed study, patients with and without embolic protection devices during TAVI will
      be repeatedly examined with a comprehensive psychiatric and cognitive test battery over a
      post-interventional period of 6 months after TAVI, with regard to the effects on mood,
      cognitive Performance and health-related quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 29, 2020</start_date>
  <completion_date type="Anticipated">May 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 29, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>cognition</measure>
    <time_frame>12 months</time_frame>
    <description>Montreal-Cognitive-Assessment, cognitive test battery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>health-related quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>Short Form (36) Health Survey (SF-36): The SF-36 consists of 8 scales. scores. Each scale is directly transformed into a 0-100 scale. A score of 100 is equivalent to no disability.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>mood</measure>
    <time_frame>12 months</time_frame>
    <description>Hospital Anxiety and Depression Scale (HADS): A person can score between 0 and 21 for either anxiety or depression); Montgomery-Ã…sberg Depression Rating Scale: usual cutoff points are: 0 to 6 - normal, 7 to 19 - mild depression, 20 to 34 - moderate depression, &gt;34 - severe Depression</description>
  </other_outcome>
  <other_outcome>
    <measure>MRI</measure>
    <time_frame>12 months</time_frame>
    <description>MRI</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>Patients with TAVI</arm_group_label>
    <description>cognitive research battery, MRI, laboratory values</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>cognitive research battery, MRI, laboratory values</intervention_name>
    <description>cognitive research battery, MRI, laboratory values</description>
    <arm_group_label>Patients with TAVI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with percutaneous aortic valve replacement
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written declaration of consent of the study participants to participate in the study
             after detailed information on the nature, significance, risks and scope of the study.

          -  Women and men between the ages of 19 and 90

          -  Clinical indication for TAVI intervention

          -  No previous psychiatric illness before TAVI

          -  No other serious disease affecting the immune system

        Exclusion Criteria:

          -  Non-compliance with the inclusion criteria

          -  Persons unable to give consent (e.g. dementia, delirium etc.)

          -  Magnetic resonance imaging (MR) contraindications

          -  ophthalmological inability to read
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Baranyi, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University Graz, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Baranyi, Prof.</last_name>
    <phone>0043-316-385-86241</phone>
    <email>an.baranyi@medunigraz.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Albrecht Schmidt, PD.</last_name>
    <phone>0043-316-385</phone>
    <email>albrecht.schmidt@klinikum-graz.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Styria</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>April 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Andreas Baranyi</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

